Biotricity Predicted To Achieve 44% Annual Growth Despite Market Risks, Analyst Says

H.C. Wainwright analyst Kevin Dede reiterated a Buy rating on Biotricity, Inc. BTCY, raising the price target to $4 from $2.

The analyst acknowledged Biotricity's sales and targeted margin growth, AI tech infusion, and the opportunity to bring its platform solution to associated cardiac-related diseases.

Dede is particularly upbeat about Biotricity's initiatives to integrate artificial intelligence for predictive analytics in chronic kidney disease to aid nephrologists in anticipating related cardiac issues.

Biotricity reported its year-end and March quarter results, with 4Q23 delivering $2.7 million in sales, up slightly from the analyst's estimate of $2.6 million.

For FY24, the analyst's sales estimate stands at $13.8 million, representing an expected 44% annual growth.

The analyst expects the stock to offer investors an opportunity to experience valuation multiple expansion on the combination of sales gains. The $4 price target represents approximately a 2.9x price-to-sales multiple on the FY24 (March) sales estimate.

Of note, Biotricity has recorded persistent, approximate 98% retention rates on its Bioflux cardiac monitoring system, exemplifying the analyst's annuity-like analogy.

On the negative side, an investment in Biotricity is subject to the risks like dilution, end-market product acceptance and pricing, and competition against companies with far greater resources, among others.

For the first quarter of FY24, the analyst expects revenues of $3.1 million, with EPS of ($0.41) loss. The analyst sees the first quarter gross profit of $1.7 million.

Price Action: BTCY shares are trading lower by 17.1% to $2.71 on the last check Wednesday.